169 related articles for article (PubMed ID: 19377865)
1. Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: a prospective open-label study.
Hammerness P; Doyle R; Kotarski M; Georgiopoulos A; Joshi G; Zeitlin S; Biederman J
Eur Child Adolesc Psychiatry; 2009 Aug; 18(8):493-8. PubMed ID: 19377865
[TBL] [Abstract][Full Text] [Related]
2. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Prasad S; Harpin V; Poole L; Zeitlin H; Jamdar S; Puvanendran K;
Curr Med Res Opin; 2007 Feb; 23(2):379-94. PubMed ID: 17288692
[TBL] [Abstract][Full Text] [Related]
3. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.
Takahashi M; Goto T; Takita Y; Chung SK; Wang Y; Gau SS
Asia Pac Psychiatry; 2014 Mar; 6(1):62-70. PubMed ID: 23857916
[TBL] [Abstract][Full Text] [Related]
4. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
5. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
Holzer B; Lopes V; Lehman R
J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):415-8. PubMed ID: 23952189
[TBL] [Abstract][Full Text] [Related]
6. Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder.
Ghuman JK; Aman MG; Ghuman HS; Reichenbacher T; Gelenberg A; Wright R; Rice S; Fort C
J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):155-66. PubMed ID: 19364293
[TBL] [Abstract][Full Text] [Related]
7. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
Chang K; Nayar D; Howe M; Rana M
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):547-51. PubMed ID: 19877979
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
[TBL] [Abstract][Full Text] [Related]
10. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
Posey DJ; Wiegand RE; Wilkerson J; Maynard M; Stigler KA; McDougle CJ
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):599-610. PubMed ID: 17069548
[TBL] [Abstract][Full Text] [Related]
11. Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
Mazzone L; Reale L; Mannino V; Cocuzza M; Vitiello B
CNS Drugs; 2011 Jun; 25(6):503-9. PubMed ID: 21649450
[TBL] [Abstract][Full Text] [Related]
12. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.
Treuer T; Gau SS; Méndez L; Montgomery W; Monk JA; Altin M; Wu S; Lin CC; Dueñas HJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):179-93. PubMed ID: 23560600
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
Wietecha LA; Williams DW; Herbert M; Melmed RD; Greenbaum M; Schuh K
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):719-30. PubMed ID: 20035590
[TBL] [Abstract][Full Text] [Related]
15. Open-label trial of atomoxetine hydrochloride in adults with ADHD.
Johnson M; Cederlund M; Råstam M; Areskoug B; Gillberg C
J Atten Disord; 2010 Mar; 13(5):539-45. PubMed ID: 19458384
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
[TBL] [Abstract][Full Text] [Related]
17. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder.
Spencer T; Biederman J; Heiligenstein J; Wilens T; Faries D; Prince J; Faraone SV; Rea J; Witcher J; Zervas S
J Child Adolesc Psychopharmacol; 2001; 11(3):251-65. PubMed ID: 11642475
[TBL] [Abstract][Full Text] [Related]
18. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study.
Wehmeier PM; Dittmann RW; Schacht A; Minarzyk A; Lehmann M; Sevecke K; Lehmkuhl G
J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):813-30. PubMed ID: 18315453
[TBL] [Abstract][Full Text] [Related]
20. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
Spencer T; Heiligenstein JH; Biederman J; Faries DE; Kratochvil CJ; Conners CK; Potter WZ
J Clin Psychiatry; 2002 Dec; 63(12):1140-7. PubMed ID: 12523874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
